38 research outputs found
Deep brain stimulation in schizophrenia
Deep brain stimulation (DBS) has successfully advanced treatment options of putative therapy-resistant
neuropsychiatric diseases. Building on this strong foundation more and more mental disorders in the
stadium of therapy-resistance are considered as possible indications for DBS. Especially schizophrenia
with its associated severe and difficult to treat symptoms is gaining attention. This attention demands
critical questions regarding the assumed mechanisms of DBS and its possible influence on the supposed
pathophysiology of schizophrenia. Here we synoptically compare current approaches and theories of
DBS and discuss the feasibility of DBS in schizophrenia as well as the transferability from other
psychiatric disorders successfully treated with DBS. For this we consider recent advances in animal
models of schizophrenic symptoms, results regarding the influence of DBS on dopaminergic
transmission as well as data concerning neural oscillation and synchronization. In conclusion the use of
DBS for some symptoms of schizophrenia seems to be a promising approach, but the lack of a
comprehensive theory of the mechanisms of DBS as well as its impact on schizophrenia might void the
use of DBS in schizophrenia at this point
Deep brain stimulation in schizophrenia
Deep brain stimulation (DBS) has successfully advanced treatment options of putative therapy-resistant
neuropsychiatric diseases. Building on this strong foundation more and more mental disorders in the
stadium of therapy-resistance are considered as possible indications for DBS. Especially schizophrenia
with its associated severe and difficult to treat symptoms is gaining attention. This attention demands
critical questions regarding the assumed mechanisms of DBS and its possible influence on the supposed
pathophysiology of schizophrenia. Here we synoptically compare current approaches and theories of
DBS and discuss the feasibility of DBS in schizophrenia as well as the transferability from other
psychiatric disorders successfully treated with DBS. For this we consider recent advances in animal
models of schizophrenic symptoms, results regarding the influence of DBS on dopaminergic
transmission as well as data concerning neural oscillation and synchronization. In conclusion the use of
DBS for some symptoms of schizophrenia seems to be a promising approach, but the lack of a
comprehensive theory of the mechanisms of DBS as well as its impact on schizophrenia might void the
use of DBS in schizophrenia at this point
Alienation: Differential Psychopathology of Ego-Disturbances
Alienation, i.e. disorders of the inner experience of integrity, continuity, and agency, represents a feature of both psychotic and non-psychotic disorders. Thereby, ego disturbances are thought to be specific for schizophrenia. Depersonalisation, in contrast, has been reported in schizophrenia as well as a neurotic, probably distinct syndrome. The differentiation of psychotic vs. non-psychotic alienation is often all but trivial. The present paper provides an overview of the historical roots and the psychopathological conceptualizations of alienation. Clinically relevant features of psychotic alienation are highlighted. Experience of passivity, loss of authenticity and disturbances of striving and volition appear as psychotic characteristics
Can quantitative EEG measures predict clinical outcome in subjects at Clinical High Risk for psychosis? A prospective multicenter study
BACKGROUND
Prediction studies in subjects at Clinical High Risk (CHR) for psychosis are hampered by a high proportion of uncertain outcomes. We therefore investigated whether quantitative EEG (QEEG) parameters can contribute to an improved identification of CHR subjects with a later conversion to psychosis.
METHODS
This investigation was a project within the European Prediction of Psychosis Study (EPOS), a prospective multicenter, naturalistic field study with an 18-month follow-up period. QEEG spectral power and alpha peak frequencies (APF) were determined in 113 CHR subjects. The primary outcome measure was conversion to psychosis.
RESULTS
Cox regression yielded a model including frontal theta (HR=1.82; [95% CI 1.00-3.32]) and delta (HR=2.60; [95% CI 1.30-5.20]) power, and occipital-parietal APF (HR=.52; [95% CI .35-.80]) as predictors of conversion to psychosis. The resulting equation enabled the development of a prognostic index with three risk classes (hazard rate 0.057 to 0.81).
CONCLUSIONS
Power in theta and delta ranges and APF contribute to the short-term prediction of psychosis and enable a further stratification of risk in CHR samples. Combined with (other) clinical ratings, EEG parameters may therefore be a useful tool for individualized risk estimation and, consequently, targeted prevention
Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments
Psychotomimetics like the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine and the 5-hydroxytryptamine2A receptor (5-HT(2A)R) agonist psilocybin induce psychotic symptoms in healthy volunteers that resemble those of schizophrenia. Recent theories of psychosis posit that aberrant encoding of prediction errors (PE) may underlie the expression of psychotic symptoms. This study used a roving mismatch negativity (MMN) paradigm to investigate whether the encoding of PE is affected by pharmacological manipulation of NMDAR or 5-HT(2A)R, and whether the encoding of PE under placebo can be used to predict drug-induced symptoms. Using a double-blind within-subject placebo-controlled design, S-ketamine and psilocybin, respectively, were administrated to two groups of healthy subjects. Psychological alterations were assessed using a revised version of the Altered States of Consciousness (ASC-R) questionnaire. As an index of PE, we computed changes in MMN amplitudes as a function of the number of preceding standards (MMN memory trace effect) during a roving paradigm. S-ketamine, but not psilocybin, disrupted PE processing as expressed by a frontally disrupted MMN memory trace effect. Although both drugs produced positive-like symptoms, the extent of PE processing under placebo only correlated significantly with the severity of cognitive impairments induced by S-ketamine. Our results suggest that the NMDAR, but not the 5-HT(2A)R system, is implicated in PE processing during the MMN paradigm, and that aberrant PE signaling may contribute to the formation of cognitive impairments. The assessment of the MMN memory trace in schizophrenia may allow detecting early phases of the illness and might also serve to assess the efficacy of novel pharmacological treatments, in particular of cognitive impairments.Neuropsychopharmacology advance online publication, 26 October 2011; doi:10.1038/npp.2011.261